OBJECTIVE: The efficacy of aprotinin in reducing blood loss after cardiopulmonary bypass is well established, although its neuroprotective potential is less well known. Furthermore, there is controversy regarding optimal dosing and possible renal complications. METHODS: Fifty-four piglets were randomized to one of 3 cardiopulmonary bypass groups designed to carry the risk of postoperative cerebral and renal dysfunction: circulatory arrest at 25 degrees C and ultra-low flow bypass (10 mL x kg(-1) x min(-1)) at either 25 degrees C or 34 degrees C. Animals were randomized to the following groups: control (no aprotinin), low dose (30,000 KIU/kg into prime only), standard full dose (30,000 KIU/kg bolus administered intravenously into prime plus 10,000 KIU/kg infusion), and double full dose. The tissue oxygenation index was monitored by means of near-infrared spectroscopy. Neurologic functional and histologic scores and creatinine and blood urea nitrogen values were outcomes of interest. RESULTS: Aprotinin significantly improved neurologic scores on postoperative day 1 after ultra-low-flow bypass at 25 degrees C or 34 degrees C (P < .01) but not after hypothermic circulatory arrest (P = .57). Linear regression indicated a strong dose-response relationship, with higher aprotinin doses having the best neurologic scores. During low-flow bypass, a higher tissue oxygenation index was correlated with a higher aprotinin dose (P < .05). Aprotinin dose had no significant effect on creatinine or blood urea nitrogen values on day 1. Low body weight was the only predictor of high blood urea nitrogen values (r = -0.39, P < .01). CONCLUSION: Aprotinin significantly improves neurologic recovery without compromising renal function in the young piglet.
OBJECTIVE: The efficacy of aprotinin in reducing blood loss after cardiopulmonary bypass is well established, although its neuroprotective potential is less well known. Furthermore, there is controversy regarding optimal dosing and possible renal complications. METHODS: Fifty-four piglets were randomized to one of 3 cardiopulmonary bypass groups designed to carry the risk of postoperative cerebral and renal dysfunction: circulatory arrest at 25 degrees C and ultra-low flow bypass (10 mL x kg(-1) x min(-1)) at either 25 degrees C or 34 degrees C. Animals were randomized to the following groups: control (no aprotinin), low dose (30,000 KIU/kg into prime only), standard full dose (30,000 KIU/kg bolus administered intravenously into prime plus 10,000 KIU/kg infusion), and double full dose. The tissue oxygenation index was monitored by means of near-infrared spectroscopy. Neurologic functional and histologic scores and creatinine and blood ureanitrogen values were outcomes of interest. RESULTS:Aprotinin significantly improved neurologic scores on postoperative day 1 after ultra-low-flow bypass at 25 degrees C or 34 degrees C (P < .01) but not after hypothermic circulatory arrest (P = .57). Linear regression indicated a strong dose-response relationship, with higher aprotinin doses having the best neurologic scores. During low-flow bypass, a higher tissue oxygenation index was correlated with a higher aprotinin dose (P < .05). Aprotinin dose had no significant effect on creatinine or blood ureanitrogen values on day 1. Low body weight was the only predictor of high blood ureanitrogen values (r = -0.39, P < .01). CONCLUSION:Aprotinin significantly improves neurologic recovery without compromising renal function in the young piglet.
Authors: R A Cardigan; I J Mackie; C Gippner-Steppert; M Jochum; D Royston; M J Gallimore Journal: Blood Coagul Fibrinolysis Date: 2001-01 Impact factor: 1.276
Authors: T Sakamoto; S Hatsuoka; U A Stock; L F Duebener; H G Lidov; G L Holmes; J S Sperling; M Munakata; P C Laussen; R A Jonas Journal: J Thorac Cardiovasc Surg Date: 2001-08 Impact factor: 5.209
Authors: Takahiko Sakamoto; David Zurakowski; Lennart F Duebener; Hart G W Lidov; Gregory L Holmes; Richard J Hurley; Peter C Laussen; Richard A Jonas Journal: J Thorac Cardiovasc Surg Date: 2004-08 Impact factor: 5.209
Authors: Eric M Graham; Andrew M Atz; Jenna Gillis; Stacia M Desantis; A Lauren Haney; Rachael L Deardorff; Walter E Uber; Scott T Reeves; Francis X McGowan; Scott M Bradley; Francis G Spinale Journal: J Thorac Cardiovasc Surg Date: 2011-11-09 Impact factor: 5.209
Authors: Toru Okamura; Nobuyuki Ishibashi; T Susheel Kumar; David Zurakowski; Yusuke Iwata; Hart G W Lidov; Richard A Jonas Journal: Ann Thorac Surg Date: 2010-12 Impact factor: 4.330
Authors: Nobuyuki Ishibashi; Yusuke Iwata; Toru Okamura; David Zurakowski; Hart G W Lidov; Richard A Jonas Journal: J Thorac Cardiovasc Surg Date: 2010-12 Impact factor: 5.209
Authors: Daryl L Reust; Jennifer A Dixon; Richard A McKinney; Risha K Patel; William T Rivers; Rupak Mukherjee; Robert E Stroud; Karen Madden; Kevin Groves; Milind Rajopadhye; Scott T Reeves; James H Abernathy; Francis G Spinale Journal: J Cardiovasc Pharmacol Date: 2011-04 Impact factor: 3.105
Authors: Paul S García; Vincent T Ciavatta; Jonathan A Fidler; Anna Woodbury; Jerrold H Levy; William R Tyor Journal: Neurochem Res Date: 2015-09-05 Impact factor: 3.996